As such, balancing the anti-proliferative effects of CDK4/6i on both tumors and lymphocytes in a way that induces tumor cell cytostasis, without compromising anti-tumor T cell immunity, will be important to maximize the clinical activity of CDK4/6i+ICI combinations. Here, CDK4 is linked to neoplasm.